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ABSTRACT
Background: PUVA treatment is
photochemotherapy for psoriasis that
combines psoralen with UVA radiation.
Although PUVA is a very effective treatment
option for psoriasis, there is an absence of
patient resources explaining and
demonstrating the process of PUVA. Studies
have shown that patients who viewed videos
explaining the treatment procedures for various
medical conditions had a greater understanding
of their treatment and were more active
participants in their health.
Objective: To present a freely available online
guide and video on PUVA treatment designed
for patient education on PUVA.
Methods: The PUVA treatment protocol used at
the University of California—San Francisco
Psoriasis and Skin Treatment Center as well as
available information from the literature was
reviewed to design a comprehensive guide for
patients receiving PUVA treatment.
Results: We created a printable guide and video
resource that reviews the benefits and risks of
PUVA, discusses the three types of PUVA
(hand–foot soak, full body soak, and systemic),
demonstrates the PUVA process, and provides
practical tips for safe use.
Conclusion: Online media and video delivers
material in a way that is flexible and often
familiar to patients. This new format is
beneficial for prospective patients planning to
undergo PUVA treatment, health-care
providers, and trainees who want to learn
more about this treatment.
Enhanced content To view enhanced content for this
article go to http://www.medengine.com/Redeem/
C9D4F0600C816B7E.
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INTRODUCTION
Psoriasis is one of the most common chronic
inflammatory skin conditions, affecting 3–4%
of the adult US population [1]. Untreated
psoriasis can reduce social, occupational, and
overall well-being [2]. Despite the availability of
topical, oral, and systemic treatments, many
patients with psoriasis, especially those with
moderate-to-severe generalized psoriasis, are
not adequately treated with an effective,
long-term treatment regimen [3].
PUVA, or psoralen plus ultraviolet A (UVA)
radiation, is one of the oldest, most effective
treatments for psoriasis. It is also known as
photochemotherapy, as it combines the use of
psoralens, a group of plant-derived compounds
that make the skin more sensitive to light, and
exposure of skin to a source of high-intensity,
long-wavelength, ultraviolet (UV) light. UV
light is a type of light given off by the sun’s
rays and can be divided into UVC
(200–280 nm), UVB (280–320 nm), and UVA
(320–400 nm). Both UVA and UVB are used for
phototherapy today. Sunlight has been utilized
throughout centuries to treat various skin
conditions, with one Indian medical text from
1500 BC describing a treatment combining
herbs (likely containing psoralens) and natural
sunlight to treat a vitiligo-like skin condition
[4]. Researchers first noticed that UV light has
an interesting effect of delaying the rapid
growth of skin cells in people with psoriasis.
They then demonstrated the effectiveness of
topical psoralens followed by UVA light in
clearing psoriatic plaques in 1974, though
research was done as early as 1970 for the
treatment of vitiligo [5].
PUVA is used to treat a range of skin diseases
in addition to psoriasis, including eczema,
vitiligo, mycosis fungoides, prurigo nodularis,
and graft-versus-host disease [6]. PUVA is
exceptionally effective. It has been shown to
reduce the Psoriasis Area and Severity Index by
75% or more (PASI-75) in 80% of patients,
which is comparable to many of the biologic
medications available today [7]. This makes
PUVA particularly useful as a second-line agent
when topical medications or UVB phototherapy
have failed. As PUVA does not affect the
immune system, it may be a more appropriate
therapy for some patients compared to other
oral and systemic treatments, which can have
the potential to cause immune suppression [7].
As part of PUVA therapy, psoralen
methoxsalen may be applied topically or taken
orally prior to exposure to UVA light. At the
University of California–San Francisco (UCSF)
Psoriasis and Skin Treatment Center, a specific
formulation of methoxsalen called Oxsoralen
Ultra (Valeant Pharmaceuticals North America
LLC, Bridgewater, NJ, USA) is used as it has
better bioavailability compared to other
formulations of methoxsalen. There are three
types of PUVA therapy: systemic PUVA
(methoxsalen taken orally), hand and foot
soak PUVA (methoxsalen dissolved in water
for hand/foot soaking), and bath PUVA
(methoxsalen dissolved in a bath tub for
whole body soaking). All three forms of PUVA
may be administered in an outpatient setting,
such as a specialized dermatologic clinic, and
patients may schedule their visits at their
convenience.
PUVA treatment is administered over the
long term in two separate phases: an initial
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clearing phase and a maintenance phase. For
each method of PUVA, during the initial
clearing phase, patients will be treated two to
three times weekly, with a minimum of 48 h in
between each session. A general estimate for
clearance is 25–30 treatment visits, or within
9–15 weeks [8–10]. However, this estimate will
vary based on diagnosis, severity of disease,
patient compliance with phototherapy
treatments, and the overall treatment regimen.
When it is determined that the psoriasis is 95%
clear, the patient will be placed on a
maintenance schedule for continuing
treatment. During the maintenance schedule,
the optimal dosing of light will be held constant
and the frequency of treatments will be steadily
decreased to as low as once per month [8, 11].
Ultimately, patients can discontinue PUVA
treatments if in stable remission. Patients can
return to PUVA treatments at the clearing
schedule should they experience a flare of the
psoriasis.
The initial dosing of UV radiation at the
UCSF Psoriasis and Skin Treatment Center is
based on the patient’s skin color and reaction to
sun exposure, also known as a Fitzpatrick skin
type, and will be determined by the medical
team. The initial dose exposure is generally
within 0.5–6 J/cm2 and may increase by
0.5–2.5 J/cm2 [11]. Throughout the treatment,
the medical team may adjust the dosing based
on the control of disease, skin redness, or burns
to maximize the safety and effectiveness of light
treatment. Furthermore, the medical team may
suggest a combination treatment consisting of
PUVA with topical vitamin D analogs, topical
corticosteroids, topical retinoids, oral retinoids,
or other systemic medications [11–13]. Of note,
however, cyclosporine and methotrexate are
typically not used in conjunction with PUVA
therapy [11, 12].
We will now describe important safety
considerations, the flow of treatment,
appropriate skin care, and possible side effects
of PUVA therapy.
METHODS
We reviewed the PUVA therapy treatment
protocol used at the UCSF Psoriasis and Skin
Treatment Center. We also performed an
English language literature search using
Pubmed including the key words ‘‘PUVA’’, or
‘‘Oxsoralen’’ or ‘‘psoralens’’ and ‘‘phototherapy’’
or ‘‘UVA’’ or ‘‘ultraviolet A’’, to identify relevant
articles to design a comprehensive guide for
patients receiving PUVA treatment.
This article does not involve any new studies
of human or animal subjects performed by any
of the authors. All photos are printed with the
consent of the subject(s).
RESULTS AND DISCUSSION
Overview
Every PUVA therapy treatment visit will
involve the patient, as well as a coordinated
care team consisting of nurses, support staff,
and/or doctors. The first portion of PUVA
treatment, involving methoxsalen (Oxsoralen
Ultra), will be undertaken by the patient and
the second portion, involving UVA radiation,
will be administered by the nurse. Methoxsalen
will be prescribed by the physician and
patients should have the prescription filled
prior to starting PUVA treatment. Patients
receiving oral systemic PUVA should set aside
at least 15 min for each appointment, while
patients receiving hand and foot soak PUVA or
bath PUVA should set aside at least 45 min
(Table 1).
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Safety Precautions
It is essential for the nursing staff and
physicians to be aware of all current patient
medications, including herbs and supplements,
and any new prescriptions prior to and during
the course of PUVA treatment, as some
medications or supplements may
photosensitize the skin. In such cases, the
UVA dose will be reduced accordingly. The
medical team should also be made aware of any
history of skin cancer prior to starting
phototherapy treatments, as PUVA may
increase the risk of skin cancer. As UVA
exposure to the eyes can cause cataracts [11],
goggles are required while in the light box.
However, important to note is that cataracts
have only been observed in animal studies,
while studies following human PUVA patients
have found no increased risk of cataracts when
proper eye protection is used [14]. Furthermore,
if no disease is present on the face, a towel is
used to cover the face. Men receiving UVA light
should use proper genital shielding to reduce
the risk of genital skin cancer. Finally, PUVA
should not be used in pregnant women, and
women who become pregnant while on PUVA
will need to stop their treatment. Contraception
is recommended to women of childbearing age
who wish to continue PUVA treatments
(Table 2).
Flow of Treatment
Every patient receiving UVA light therapy will
check in at the front desk and gather all
necessary supplies, including goggles, a gown,
towels, and genital covering for men. Patients
receiving hand and foot soak PUVA or bath
PUVA should also get a measuring cup and
additional towels. Prior to stepping into the
UVA light box, patients receiving the three
different types of PUVA will follow three
different protocols, as described below.
For systemic PUVA treatment, patients must
take methoxsalen by mouth 75 min prior to
each of their scheduled appointment times.
Methoxsalen may be taken at home or
anywhere the patient feels comfortable, so
long as it is taken 75 min prior to entering the
light box. The dose of methoxsalen is modified
Table 1 Overview of PUVA phototherapy
Three types of PUVA therapy: systemic PUVA (taken
orally), hand and foot soak PUVA, and bath PUVA
Initial frequency of 2–3 sessions per week
Appointments last between 15–45 min
Minimum 48-h interval between each session
Clearance rates around 80%, typically requiring 25–30
sessions
Oxsoralen Ultra prescription must be filled prior to the
first treatment visit
Administered in 2 separate phases: clearing phase and
maintenance phase
PUVA psoralen plus ultraviolet A
Table 2 Safety precautions for PUVA phototherapy
Disclosure of all current medications, herbs, and
supplements
Disclosure of any history of skin cancer
Eye examinations required prior to PUVA therapy and
annually thereafter
Eye protection with goggles
Face shielding with towel
Male genital coverage with cone or towela
Will not be used during pregnancy
PUVA psoralen plus ultraviolet A
a Unless an exception has been granted
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for each patient based on individual body
weight, at a ratio of 0.4–0.6 mg/kg of weight.
Each patient should follow the specific
instructions written on the prescription
(Table 3a).
For hand and foot soak PUVA, patients will use
their measuring cup to mix 10 mg of methoxsalen
with 2 quarts of warm water for just hands or feet,
or 20 mg of methoxsalen with 4 quarts of warm
water for both hands and feet (the exact mixture
ratio may vary; each patient should follow the
specific instructions written on the prescription).
Water can come from a warm water sink or can be
microwaved. Mixing the methoxsalen with warm
water will cause the pill to dissolve and the
solution will turn into a light aquamarine color.
It is helpful if the nurse demonstrates this process
during the initial treatment visits. The nurse will
want to examine the hands and feet prior to
soaking in solution to determine a proper light
dose. After making the solution, the affected areas
on the hands and/or feet will be soaked within the
solution for 30 min prior to light exposure. After
soaking, the solution should be discarded into the
sink and hands and feet dried prior to returning to
the nurses’ station for the UVA treatment.
Patients should only dry, not rinse off, after
soaking (Table 3b; Fig. 1).
Bath PUVA involves soaking in a bathtub for
30 min prior to light exposure. Patients will
dissolve 50 mg of methoxsalen in a measuring
cup filled with hot water. The solution should
be mixed until an aquamarine-colored solution
is formed. This solution will then be added to a
bathtub that is prefilled with 100 L of warm
water. Nursing staff will demonstrate this
process during the initial treatment visits. The
nurse will want to examine the skin prior to
soaking in solution to determine a proper light
dose. Timers will be available in each bathroom,
so that patients may be able to time their soak
for 30 min. It is important to note that soaking
in the tubs should only be done from the
shoulders down to the feet. The face should
never be soaked. After soaking for 30 min,
patients should carefully step out of the bath
and dry off without showering off the bath
solution. Patients may then drain the solution
and notify the nursing staff that they are ready
for the light box treatment (Table 3c; Fig. 2).
Once patients are ready for the light
treatment, they will be guided by the nurses to
the UVA light box. Patients treated with hand
and foot soak PUVA will be using a specialized
light box that accommodates only the hands
and/or feet. Those being treated with systemic
or bath PUVA will step into a whole body light
box. After making sure that all safety
precautions are followed, including goggles
and genital shielding, the nurse may wrap the
patient’s face in a towel. The nurse will position
the patient in a way that will maximize light
penetration and this position will be
maintained during the entire light treatment
to clear the disease effectively and prevent
burns. The nurse will then set the light
settings according to the patient’s needs. Light
will shine on the patient for several seconds to
minutes depending on the patient’s individual
dose. While in the light box, it is important for
patients to keep their eyes closed and goggles
on, and bulbs should not be touched. Following
the UVA light treatment, the patient may return
to the dressing room to get dressed and the
treatment session is complete. At each
subsequent treatment session, the dose of light
(duration of light treatment) will be adjusted
depending on the patient’s reaction to the
previous treatment session.
Post-phototherapy Skin Care
It is important to take good care of the skin after
each treatment session. Methoxsalen can cause
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Table 3 Flow of treatment for PUVA phototherapy
(a) Oral systemic PUVA
Patient ingests Oxsoralen Ultra 75 min prior to appointment
↓
Patient checks in at front desk
↓
Patient gathers supplies (gown, towels, goggles, genital coveragea)
↓
Patient changes into gown and nurse examines patients skin 
↓
Patient enters UVA box 
↓
Nurse adjusts light box settings 
↓
Patient undergoes session
(b) Hand and foot soak PUVA
Patient checks in at front desk
↓
Patient gathers supplies (gown, towels, goggles, measuring cup, genital coveragea)
↓
Patient mixes 10 mg of Oxsoralen Ultra with 2 quarts of warm water
↓
Patient changes into gown and nurse examines patients skin prior to soaking 
↓
Affected areas of hands/feet soaked in Oxsoralen Ultra solution for 30 min
↓
Patients should dry, not rinse, after soaking then retrieve nurse
↓
Patient enters hands and/or feet into UVA box 
↓




Patient checks in at front desk
↓
Patient gathers supplies (gown, towels, goggles, measuring cup, genital coveragea)
↓
Patient mixes 50 mg of Oxsoralen Ultra in a cup with warm water
↓
Patient changes into gown and nurse examines patients skin prior to soaking 
↓
Oxsoralen Ultra solution is added to a bathtub prefilled with 100 L warm water
↓
Patients should soak only from shoulders down to feet for 30 min
↓
Patients should dry, not rinse, after soaking then retrieve nurse
↓
Patient enters UVA box 
↓
Nurse adjusts light box settings 
↓
Patient undergoes session
PUVA Psoralen plus ultraviolet A
a Genital coverage may be required for male patients unless an exception has been granted
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the skin to become more sensitive to light and,
therefore, patients are more susceptible to
sunburn. Patients should avoid exposure to
sunlight, even through window glass, for 24 h
after treatment with PUVA. Patients should
apply sunscreen with Sun Protection Factor
(SPF) of 15 or above to any sun-exposed skin
for at least 24 h after PUVA treatment.
Sunscreen should be reapplied every 1.5 h if
outdoors. Patients should also use moisturizers
and lotions on the affected areas at least twice
daily as part of their routine skin care regimen.
Care should be taken to avoid scrubbing the
skin, as any trauma or breakdown of the skin
can potentially cause worsening of psoriasis in a
process called the Koebner phenomenon.
Patients should limit makeup and nail polish
on areas receiving treatment to allow full light
penetration. While perfume and colognes are
fine when applied to clothes, they should not be
applied to skin, as some of the chemicals may be
photosensitizing and may increase the risk of
burning during PUVA treatment. Lastly, it is
important to limit sunbathing during the
Fig. 1 Hand and foot soak PUVA treatment procedure Fig. 2 Bath PUVA treatment procedure
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clearing stage of PUVA treatment to reduce the
risk of sunburn, which can interfere with the
PUVA treatment regimen (Table 4).
Side Effects
There are some risks and possible side effects of
PUVA treatment. Some of the potential
short-term side effects include burning,
itching, and pigmentation of the skin. Burns,
which often appear as redness, tenderness, and
blistering, may start 24–72 h after treatment in
up to 10% of patients during the clearance
phase [15]. For mild burns, a topical
corticosteroid cream or ointment may be
applied as directed. Mild itching is common
and can usually be relieved with topical
emollients. A moderate-to-deep tan may
develop while on treatment, but often fades
6–8 weeks after stopping treatment. Nausea is
the most common side effect unique to
systemic PUVA and may be reduced by taking
methoxsalen with protein, milk, or a full meal.
Long-term risks of PUVA treatment include
cataracts, skin aging changes, and skin cancer.
Cataracts are considered a theoretical risk, as
studies on humans with proper eye protection
have not confirmed an increase in the risk of
cataracts with UVA exposure [14]. Skin aging
changes may include dryness, wrinkling, and
freckling, which may disappear after treatment is
stopped, though freckling may persist
indefinitely. PUVA can lead to an increased risk
of non-melanoma and melanoma skin cancers,
particularly among light-skinned individuals
and those who have previously received X-rays
or Grenz rays [16]. The risk of genital skin cancer
Table 4 Post-phototherapy skin care for PUVA
phototherapy
Avoid exposure to sunlight and use sunscreen of SPF 15
or higher for at least 24 h after PUVA
Moisturize skin twice daily and frequently in between
treatments
Avoid scrubbing skin hard or tearing off skin
Limit nail polish and makeup on areas receiving
treatment
Avoid perfumes and colognes directly on skin
Avoid sunbathing during the clearing stage of PUVA
treatment
PUVA psoralen plus ultraviolet A, SPF sun protection
factor
Table 5 Side effects of PUVA phototherapy
Side effect Signs/symptoms
Short term
Burning Redness, tenderness, tightness,
blistering
Noticeable 24–72 h after
treatment
Itching Usually mild and relieved with
emollients
Nausea Unique to oral systemic PUVA
Reduced by consuming
Oxsoralen Ultra with
protein, milk, or full meal
Tanning Skin darkening
Long term
Photoaging Coarseness, wrinkling, laxity,
increased fragility, freckling
Cataracts Blurry vision, as though looking
through frosted glass
Theoretical risk that has not
been confirmed in humans




Unusual shaped growths or
lumps may appear to grow
quickly over time
Genital skin cancer possible,
but prevented with shielding
PUVA psoralen plus ultraviolet A
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may also be increased, but may be prevented with
proper shielding (Table 5) [17].
CONCLUSIONS
PUVA treatment is a very effective and safe
treatment option for patients whose psoriasis is
not well controlled on topical therapies alone.
PUVA may also be a viable option for patients
who have failed UVB therapy. PUVA requires
patient compliance with consistent treatments
for 9–15 weeks to achieve maximal results.
When administered and monitored properly,
PUVA can help patients safely achieve clearance
and in many cases provide long-lasting
remission. The effectiveness of PUVA is
comparable to some of the most effective
biologic agents available today for the
treatment of moderate-to-severe psoriasis. It is
our hope that this guide can serve as a valuable
resource for patients considering or preparing
for PUVA treatment and the health-care
providers who treat these patients.
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